Kokubunji, Japan

Nobuo Kawaguchi

This inventor holds 1 USPTO granted patent. Top assignee: Fujisawa Pharmaceutical Company, Ltd.. Active years: 1980.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nobuo Kawaguchi. Retrieved from https://idiyas.com/inventor/nobuo-kawaguchi-e2bkeiad

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1980

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Nobuo Kawaguchi: Innovator in Antiallergic Methods

Introduction

Nobuo Kawaguchi is a notable inventor based in Kokubunji, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in developing antiallergic methods. His work has implications for improving the quality of life for individuals suffering from allergies.

Latest Patents

Kawaguchi holds 1 patent related to antiallergic methods. His patent describes compounds of the formula: ##STR1## wherein R.sub.1 and R.sub.2 are each hydrogen or methyl. These compounds have been found to be effective in relieving allergic symptoms by inhibiting histamine release from mast cells. They can be utilized in free form or as pharmaceutically acceptable acid addition salts.

Career Highlights

Kawaguchi is associated with Fujisawa Pharmaceutical Company, Ltd., where he has been instrumental in advancing research in allergy treatments. His innovative approach has led to the development of new therapeutic options for patients.

Collaborations

Kawaguchi has collaborated with notable colleagues, including Hiroyuki Kikuchi and Hideaki Shiokawa. Their combined expertise has contributed to the success of their projects and the advancement of their research.

Conclusion

Nobuo Kawaguchi's work in antiallergic methods showcases his dedication to improving healthcare solutions. His contributions continue to impact the pharmaceutical industry positively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…